Apex drug regulator greenlights Serum’s covid and influenza combination vaccine trial; also approves Omicron vaccine

New Delhi: India’s apex drug regulator has approved the third phase of clinical trials for the country’s first combined covid-19 and influenza vaccine from Serum Institute of India (SII), according to two government officials and documents reviewed by. mint. In what is being viewed as a shot in the arm for India’s healthcare playbook, a…

Read More

Can the strong order inflow lift ABB’s earnings?

Against this backdrop, the stock trading at 65 times 2026 earnings estimates, according to Bloomberg Consensus appears steep. Note that despite the strong inflow, the order backlog of ₹Rs 10,471 crore translates to less than 0.8 times ABB’s 2025 revenue, providing limited earnings visibility. Besides, the robotics segment accounted for a significant part of Q4…

Read More

Your next boss might be a chief AI officer.

Over the past 12 months, companies have announced at least 50 senior AI-focused leadership hires—most notably chief AI officers (CAIOs)—across fintech, banking, manufacturing, logistics, media and enterprise technology, according to executive search firm Longhouse. The pace has accelerated sharply over the past six months, with more than a third of these appointments announced between November…

Read More

PI Industries pins hope on Q4. Why investors aren’t buying the optimism?

Agrochemicals company PI Industries Ltd is having a hard time navigating demand headwinds and the US tariff impact. In the December quarter (Q3FY26), consolidated revenue declined year-on-year and sequentially to ₹1,376 crore, sharply missing consensus estimate of ₹Rs 1,770 crore. At the core of this disappointment is its custom synthesis and manufacturing (CSM) business, which…

Read More